Ovarian adenoma benign

Summary

Ovarian adenoma benign (MONDO:0005179) is a cancer. A subtype of ovarian benign neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ovarian adenoma benign
Mondo ID	MONDO:0005179
Anatomy (UBERON)	UBERON:0000992
Is cancer (heuristic)	yes

Disease family

This is a subtype of ovarian benign neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › benign neoplasm › benign reproductive system neoplasm › benign female reproductive system neoplasm › ovarian benign neoplasm › ovarian adenoma benign

Related subtypes (14): benign struma ovarii, ovarian endometrioid adenofibroma, ovarian clear cell adenofibroma, ovarian surface papilloma, ovarian mucinous adenofibroma, rete ovarii cystadenofibroma, ovarian serous adenofibroma, ovarian fibroma, serous or mucinous cystadenoma of childhood, Meigs syndrome, pseudo-Meigs syndrome, atypical Meigs syndrome, benign ovarian sex cord-stromal tumor, benign ovarian mucinous tumor

Subtypes (2): rete ovarii adenoma, ovarian cystadenoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.